ONCOSCOPE® (ANWA)-S Indication
Based on the available evidence, I cannot provide a definitive indication for ONCOSCOPE® (ANWA)-S as this specific optical biopsy system is not mentioned in any of the provided guidelines or research studies.
What the Evidence Shows
The provided guidelines and research focus on:
- Standard surveillance protocols for Barrett's esophagus using high-definition white-light endoscopy with Seattle biopsy protocol 1
- Wide-Area Transepithelial Sampling (WATS-3D) as an adjunctive technique, though the 2025 AGA guideline makes no recommendation for or against its use (knowledge gap) 1
- Optical coherence tomography (OCT) as a research tool for identifying dysplasia 2, 3
- Virtual chromoendoscopy (such as narrow-band imaging) as standard practice 4, 5
Key Distinction
ONCOSCOPE® (ANWA)-S appears to be a distinct optical biopsy system that is not addressed in current major guidelines from the AGA (2025) 1 or ESGE (2023) 5. The research studies discussing optical technologies focus on OCT and angle-resolved low coherence interferometry (a/LCI) 2, 3, but do not reference ONCOSCOPE® specifically.
Clinical Context
For Barrett's esophagus surveillance, current guideline-endorsed approaches include:
- High-definition white-light endoscopy with virtual chromoendoscopy as standard of care 4, 5
- Seattle biopsy protocol: 4-quadrant biopsies every 1-2 cm 1, 5
- Targeted biopsies of all visible lesions 1, 5
Without specific FDA labeling or guideline endorsement for ONCOSCOPE® (ANWA)-S, I cannot recommend its use or define its indication in Barrett's esophagus surveillance. Clinicians should refer to the device's FDA-approved labeling if available, or await incorporation into evidence-based guidelines before routine clinical implementation.